Neuronetics (STIM)
NASDAQ:STIM
Want to see STIM full AI Analyst Report?
STIM Stock Chart & Stats
$1.42
-$0.02(-1.30%)
At close: 4:00 PM EST
$1.42
-$0.02(-1.30%)
Day’s Range― - ―
52-Week Range$0.80 - $4.85
Previous CloseN/A
Volume92.55K
Average Volume (3M)2.64M
Market Cap
$91.16M
Enterprise Value$118.04M
Total Cash (Recent Filing)$13.21M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 04, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding69,587,840
10 Day Avg. Volume1,645,722
30 Day Avg. Volume2,638,108
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.07
Price to Sales (P/S)0.61
P/FCF Ratio-4.30
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue0.78
Enterprise Value/Gross Profit1.62
Enterprise Value/Ebitda-4.59
Forecast
1Y Price Target
$3.00Price Target Upside111.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.46
Revenue Forecast (FY)$161.08M
Bulls Say, Bears Say
Bulls Say
Strong Revenue ReboundA 166% TTM revenue rebound indicates durable recovery in product and clinic demand, expanding the installed base and recurring revenue potential. Sustained top-line momentum supports scaling fixed-cost leverage and increases the probability of reaching breakeven as utilization and service revenue grow.
Healthy Gross MarginsMid-to-high 40s gross margins provide a structural cushion to fund commercial and R&D investment while moving toward profitability. If maintained, these margins allow operating expense cuts to flow more directly to operating income, improving cash conversion as revenue scales.
Expanded Payer AccessExpanded coverage through major payers meaningfully increases the addressable market and lowers adoption friction long-term. Broader provider authorization can raise referral volumes and utilization across clinics, supporting sustainable recurring treatment revenue and network effects for NeuroStar adoption.
Bears Say
Continued Cash BurnA multi‑million dollar projected operating cash shortfall for the year signals ongoing funding needs and constrains strategic optionality. Even with sequential improvement, persistent negative cash flow raises refinancing risk, may force dilutive financing or spend cuts, and compresses runway for growth initiatives.
Elevated Leverage, Thin EquityA pressured capital structure with high leverage and limited equity cushion increases vulnerability to revenue shocks and limits balance-sheet flexibility. Debt service and past principal repayments have consumed cash, reducing ability to invest ahead of demand or absorb execution setbacks without external financing.
Persistent GAAP LossesA sustained net margin near -25% and continued negative EBITDA require prolonged revenue growth and disciplined cost control to reach break‑even. Ongoing losses increase dependence on external capital and heighten execution risk if utilization, reimbursement, or clinic performance falter.
Neuronetics News
STIM FAQ
What was Neuronetics’s price range in the past 12 months?
Neuronetics lowest stock price was $0.80 and its highest was $4.85 in the past 12 months.
What is Neuronetics’s market cap?
Neuronetics’s market cap is $91.16M.
When is Neuronetics’s upcoming earnings report date?
Neuronetics’s upcoming earnings report date is Aug 04, 2026 which is in 53 days.
How were Neuronetics’s earnings last quarter?
Neuronetics released its earnings results on May 05, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.174 by $0.014.
Is Neuronetics overvalued?
According to Wall Street analysts Neuronetics’s price is currently Undervalued.
Does Neuronetics pay dividends?
Neuronetics does not currently pay dividends.
What is Neuronetics’s EPS estimate?
Neuronetics’s EPS estimate is -0.12.
How many shares outstanding does Neuronetics have?
Neuronetics has 69,587,840 shares outstanding.
What happened to Neuronetics’s price movement after its last earnings report?
Neuronetics reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.174. Following the earnings report the stock price went up 7.426%.
Which hedge fund is a major shareholder of Neuronetics?
Currently, no hedge funds are holding shares in STIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuronetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (111.27% Upside)
$3.00 (111.27% Upside)
Blogger Sentiment
Bullish
STIM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 56.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.70%
12-Months-Change
Fundamentals
Return on Equity
-164.68%
Trailing 12-Months
Asset Growth
-11.65%
Trailing 12-Months
Company Description
Neuronetics
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
STIM Company Deck
STIM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a mixed but constructive view: top-line growth (total revenue +8%, clinic revenue +15%), improved profitability trends (narrower net loss and $2.0M adjusted EBITDA improvement), and meaningful operational initiatives (cost savings, go-to-market pilots, payer/regulatory tailwinds). Offsetting these positives are ongoing challenges including NeuroStar treatment revenue declines, gross margin contraction, a materially reduced cash balance ($19.0M vs $34.1M at year-end), continued GAAP losses and a near-term projected operating cash burn for the year. Management emphasized discipline, cash-flow focus, and pilots to expand reach — signaling a path to stabilization but with execution and liquidity risks to manage in the near term.View all STIM earnings summariesSTIM Stock 12 Month Forecast
Average Price Target
$3.00
▲(111.27% Upside)
Technical Analysis
Ownership Overview
51.32% Insiders
5.63% Mutual Funds
4.82% Other Institutional Investors
31.97% Public Companies and
Individual Investors